In steadfast resistance against dilution, I was wrongIf TLT can operate free of financial concern for two years or more, the potential here is staggering. Understandably, NMIBC ph2 is the overwhelming value driver. But being fully cashed up with easily convertible warrants also allows faster progress on other cancer indications as they enter human testing.
Forgotten in all of this is the cool laser therapy business. For those that remember, TLT's non-drug treatment for a host of connective-tissue ailments - and the associated, almost instant pain relief - was endorsed by a number of high profile athletes and professional sports franchises in major league baseball, hockey, football, basketball and others.
The current strategy for the cool laser business is to generate recurring revenue through a Software-As-A-Service (SAAS) offering. Any business model based on recurring revenue has a better than average chance of succeeding, IMHO.
I was vehemently opposed to a full cash up at current prices. Now, after cooling off and even warming to the idea, I support a full and undoubtedly over-subcribed offering.